Physician profile
Azra Raza
NPI 1104809656
$34,055.57
in general payments reported to CMS, 2019-2025
14 companies · $3,441 in 2025
The $3,441 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.36 · 2020: $30.71 · 2021: $17K · 2022: $4,907 · 2023: $23.23 · 2024: $9,077 · 2025: $3,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,000.00 |
| Food and Beverage | $541.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $16,000.00 | 2021-2025 | Tazverik |
| Genzyme Corporation | $6,904.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,000.00 | 2021 | |
| Taiho Oncology, INC. | $3,872.66 | 2022 | |
| Janssen Global Services, LLC | $1,625.00 | 2021 | |
| Celgene Corporation | $531.84 | 2022-2025 | Reblozyl |
| Roche Diagnostics Corporation | $47.36 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $30.71 | 2020 | |
| Teleflex LLC | $15.76 | 2024 | Arrow |
| Incyte Corporation | $14.25 | 2022 | |
| Becton, Dickinson and Company | $13.99 | 2024 | Trek |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azra Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.